SCHEMBL56884

SCHEMBL56884

O=Cc1cc2ccccc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 1.00
GSK3B P49841 1/20 0.50
BCL2L1 Q07817 1/20 0.47
ERN1 O75460 2/20 0.46
CA2 P00918 2/20 0.46
TUBB4A P04350 2/20 0.45
TUBB P07437 2/20 0.45
TUBA3C P0DPH7 2/20 0.45
TUBA1B P68363 2/20 0.45
TUBA4A P68366 2/20 0.45
TUBB4B P68371 2/20 0.45
TUBB3 Q13509 2/20 0.45
TUBB2A Q13885 2/20 0.45
TUBB8 Q3ZCM7 2/20 0.45
TUBA3E Q6PEY2 2/20 0.45
TUBA1A Q71U36 2/20 0.45
TUBA1C Q9BQE3 2/20 0.45
TUBB6 Q9BUF5 2/20 0.45
TUBB2B Q9BVA1 2/20 0.45
TUBB1 Q9H4B7 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629031 1.00 CYP2A6 (1.00) CYP2A6GSK3BBCL2L1ERN1CA2
Hydrochloric Acid SCHEMBL31458505 0.98 CYP2A6 (0.96) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL17666728 0.83 CYP2A6 (0.71) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL8038999 0.80 CYP2A6 (0.67) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL8038997 0.80 CYP2A6 (0.67) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL2902480 0.80 CYP2A6 (0.67) CYP2A6GSK3BBCL2L1CA2TUBB4A
SCHEMBL30828502 0.79 CYP2A6 (0.66) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL7416778 0.78 CYP2A6 (0.64) CYP2A6GSK3BBCL2L1ERN1CA2
SCHEMBL7079637 0.78 CYP2A6 (0.64) CYP2A6GSK3BBCL2L1CA2TUBB4A
SCHEMBL1567214 0.78 CYP2A6 (0.64) CYP2A6GSK3BBCL2L1CA2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415802-B1 Dipyridine benzothiophene derivative compound King Faisal University (SA) 2025-09-16 US claimed
CN-120117974-A Synthetic method for preparing di-deuterated primary alcohol by catalytic aldehyde hydrogenation and hydrogen-deuterium exchange reaction 中国科学院大连化学物理研究所 2025-06-10 CN claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
CN-118854671-A Mildew-proof cotton yarn and processing technology thereof 苍南县骏博纺织有限公司 2024-10-29 CN claimed
CN-118684596-A 2-Imine-3-carbonyl-propionamide compound, and preparation method and application thereof 上海大学 2024-09-24 CN claimed
CN-114791423-B Preparation method and application of fluorescence sensor for glyphosate detection 哈尔滨理工大学 2024-08-09 CN claimed
CN-118026796-A Synthetic method for decarbonylation deuteration reaction of rhodium-catalyzed aldehyde compound 中国科学院大连化学物理研究所 2024-05-14 CN claimed
CN-116640106-B Phenylpiperazine compound and preparation method and application thereof 郑州大学 2024-03-08 CN claimed
CN-116640106-A Phenylpiperazine compound and preparation method and application thereof 郑州大学 2023-08-25 CN claimed
CN-114836201-A Zinc ion mediated fluorescence sensor and preparation method and application thereof 哈尔滨理工大学 2022-08-02 CN claimed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 WO claimed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP claimed
WO-2002092563-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-11-21 WO claimed
CN-1082959-C Substituted benzothienylpiperazines their use as medicaments, and processes for their preparation AVENTIS PHARMACEUTICAL INC (US) 2002-04-17 CN claimed
EP-0732332-B1 Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation AVENTIS PHARMA INC (US) 2001-12-19 EP claimed
US-6316620-B1 AS LIGANDS TO TRANSITION METALS WHICH ARE USED AS CATALYSTS IN SYNTHESIZING ASYMMETRIC COMPOUNDS TO OBTAIN SPECIFIC ENANTIOMERS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-11-13 US claimed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO claimed
US-5801176-A ANTIPSYCHOTIC AGENTS HOECHST MARION ROUSSEL, INC. 1998-09-01 US claimed
CN-1139108-A Substituted benzothienylpiperazines their use as medicaments, and processes for their preparation HOECHST MARION ROUSSEL INC (US) 1997-01-01 CN claimed
EP-0732332-A1 Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation HOECHST MARION ROUSSEL, INC. (US) 1996-09-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415802-B1 Dipyridine benzothiophene derivative compound MAVS, DPP4, EIF2AK2 CYP2A6 2778/4885GSK3B 2979/4885BCL2L1 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.